TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05097729

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial Magnetic Stimulation
Description: The brain stimulation can be delivery using different devices; in this project a MagPro X100 stimulator connected to a MagPro Cool-B65 liquid-cooled butterfly coil (MagVenture A/S, Farum, Denmark) will be used. Resting motor threshold (M1-rTMS) will be determined during the visit 1 or visit 2 and used along all visits. The rTMS pulse sequences and intensities used are all within the published safety guidelines

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Transcranial Magnetic Stimulation
Description: The brain stimulation can be delivery using different devices; in this project a MagPro X100 stimulator connected to a MagPro Cool-B65 liquid-cooled butterfly coil (MagVenture A/S, Farum, Denmark) will be used. Resting motor threshold (M1-rTMS) will be determined during the visit 1 or visit 2 and used along all visits. The rTMS pulse sequences and intensities used are all within the published safety guidelines

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcranial Magnetic Stimulation
Description: The brain stimulation can be delivery using different devices; in this project a MagPro X100 stimulator connected to a MagPro Cool-B65 liquid-cooled butterfly coil (MagVenture A/S, Farum, Denmark) will be used. Resting motor threshold (M1-rTMS) will be determined during the visit 1 or visit 2 and used along all visits. The rTMS pulse sequences and intensities used are all within the published safety guidelines
Study: NCT06007365

Intervention type: DEVICE
Intervention: Z5m Dental Implants
Description: This is an observational study, collecting data on the use of Z5m Dental Implants.
Study: NCT04973020

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR6390、efavirenz
Description: SHR6390 tablet single dose；Efavirenz single dose.
Study: NCT04825171

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bryophyllum 50 % Chewing Tablets
Description: Each 350 mg tablet corresponds to 170 mg of leave press juice from Bryophyllum pinnatum, dried down to 17 mg by mixing with lactose; 100 mg dried BP matter in 1 g.
Study: NCT06321289

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Allogeneic CD19-STAR T cell
Description: Phase 1 dose escalation (3+3): dose 1 (2×10\^6 cells/kg), dose 2 (6×10\^6 cells/kg), dose 3 (1.8×10\^7 cells/kg); Phase 2: dose of RP2D. No more than 5 × 10\^4 per kilogram of allogenic residual TCR-positive T cells harbouring in grafts can only be released for recipient infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Intravenous fludarabine 30-50 mg/m\^2/day on days -5, -4, and -3.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Intravenous cyclophosphamide 500-1000 mg/m\^2/day on days -5, -4, and -3.
Study: NCT04700527

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Short Chain Fatty Acid
Description: Participants will take the supplement as prescribed to determine if it can help with GI toxicity

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Tapioca Flour
Description: Participants taking this will be used as a control group compared to those receiving the SCFA supplement
Study: NCT05553366

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VX-548
Description: Tablets for oral administration.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: HB/APAP
Description: Capsules for oral administration.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo (matched to VX-548)
Description: Placebo matched to VX-548 for oral administration.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (matched to VX-548)
Description: Placebo matched to VX-548 for oral administration.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (matched to HB/APAP)
Description: Placebo matched to HB/APAP for oral administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo (matched to HB/APAP)
Description: Placebo matched to HB/APAP for oral administration.
Study: NCT04925986

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sitravatinib
Description: Groups 1A and 2A receive Sitravatinib 100mg orally (PO) daily starting on cycle 1 day 1 (C1D1). Groups 1B and 2B) receive Sitravatinib 100mg orally (PO) daily starting on Cycle 2 Day 1 (C2D1).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sitravatinib
Description: Groups 1A and 2A receive Sitravatinib 100mg orally (PO) daily starting on cycle 1 day 1 (C1D1). Groups 1B and 2B) receive Sitravatinib 100mg orally (PO) daily starting on Cycle 2 Day 1 (C2D1).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sitravatinib
Description: Groups 1A and 2A receive Sitravatinib 100mg orally (PO) daily starting on cycle 1 day 1 (C1D1). Groups 1B and 2B) receive Sitravatinib 100mg orally (PO) daily starting on Cycle 2 Day 1 (C2D1).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sitravatinib
Description: Groups 1A and 2A receive Sitravatinib 100mg orally (PO) daily starting on cycle 1 day 1 (C1D1). Groups 1B and 2B) receive Sitravatinib 100mg orally (PO) daily starting on Cycle 2 Day 1 (C2D1).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: All groups (1A, 1B, 2A, 2B) receive Pembrolizumab 200mg intravenous every three weeks (IV Q3w) on cycle 1 day 1 (C1D1).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: All groups (1A, 1B, 2A, 2B) receive Pembrolizumab 200mg intravenous every three weeks (IV Q3w) on cycle 1 day 1 (C1D1).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: All groups (1A, 1B, 2A, 2B) receive Pembrolizumab 200mg intravenous every three weeks (IV Q3w) on cycle 1 day 1 (C1D1).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: All groups (1A, 1B, 2A, 2B) receive Pembrolizumab 200mg intravenous every three weeks (IV Q3w) on cycle 1 day 1 (C1D1).
Study: NCT06321926

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ActiveWaiting App
Description: The final prototype aims at increasing physical activity during the day by providing exercises for waiting periods and other idle time periods. The user can choose from a pool of exercises from five different categories (11 exercises for endurance, 65 exercises for strength, 67 exercises for flexibility, 11 exercises for relaxation, or 5 exercises for balance). Additionally, within each category, the user can choose only discrete exercises which are not noticeable to an observer. If the user has used the app before, the last or previously saved settings can be chosen. Every input field has an information icon showing a short description of the input field.

Intervention type: DEVICE
Group type: OTHER
Intervention: ActiveWaiting App
Description: The final prototype aims at increasing physical activity during the day by providing exercises for waiting periods and other idle time periods. The user can choose from a pool of exercises from five different categories (11 exercises for endurance, 65 exercises for strength, 67 exercises for flexibility, 11 exercises for relaxation, or 5 exercises for balance). Additionally, within each category, the user can choose only discrete exercises which are not noticeable to an observer. If the user has used the app before, the last or previously saved settings can be chosen. Every input field has an information icon showing a short description of the input field.
Study: NCT04731038

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anlotinib, Toripalimab, Paclitaxel, Cisplatin/ Carboplatin
Description: This is a single-arm study with all patients receiving these four drugs.
Study: NCT06232512

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Haptic Device
Description: Provides sensory substitution by mapping pressure from the insole sensor onto a corresponding vibrating and heating patch to be worn where more sensation is present.
Study: NCT05394220

Intervention type: DIAGNOSTIC_TEST
Intervention: 16S rRNA gene amplicon sequencing
Description: molecular sequencing for the microbiome in parapneumonic effusion

Intervention type: DIAGNOSTIC_TEST
Intervention: 16S rRNA gene amplicon sequencing
Description: molecular sequencing for the microbiome in parapneumonic effusion
Study: NCT05514704

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise Therapy via video conference
Description: The intervention will include the different levels of the following exercises that are given to the patient considering their functional level:~1. Straight leg raise (Level 1-2-3)~2. Quadriceps strengthening (Level 1-2-3)~3. Hip abductor/adductor strengthening (Level 1-2-3)~4. Hamstring stretch~5. Gastrocnemius stretch

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise Therapy via mobile application
Description: The intervention will include the different levels of the following exercises that are given to the patient considering their functional level:~1. Straight leg raise (Level 1-2-3)~2. Quadriceps strengthening (Level 1-2-3)~3. Hip abductor/adductor strengthening (Level 1-2-3)~4. Hamstring stretch~5. Gastrocnemius stretch
Study: NCT04103489

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eculizumab
Description: Participants will receive eculizumab at diagnosis of HELLP syndrome. Participants will receive a maximum of 4 doses.
Study: NCT05735808

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Physician based education
Description: Regular education provided by physician

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: VR based education
Description: VR based education
Study: NCT05696275

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: exercise
Description: 20-30 minutes of walking and elastic band exercise per day
Study: NCT05589779

Intervention type: OTHER
Intervention: Asthma and cardiovascular disease
Description: To know the clinical and inflammatory characteristics of patients with asthma and associated cardiovascular disease, as well as their relationship with eosinophil subtypes, biomarkers of chronic inflammation and bronchial remodeling.

Intervention type: OTHER
Intervention: Asthma and cardiovascular disease
Description: To know the clinical and inflammatory characteristics of patients with asthma and associated cardiovascular disease, as well as their relationship with eosinophil subtypes, biomarkers of chronic inflammation and bronchial remodeling.
Study: NCT05804643

Intervention type: PROCEDURE
Intervention: Diffusion magnetic resonance imaging
Description: Free water elimination diffusion MRI and diffusion kurtosis MRI techniques
Study: NCT05057260

Intervention type: OTHER
Intervention: No drug invervention
Description: No clinical trial
Study: NCT06094751

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ACT Guide for Insomnia
Description: ACT Guide for Insomnia includes 2 modules. Module 1 will include sleep/insomnia education, ACT skills (acceptance, defusion), and behavioral change. Module 2 will include sleep restriction, sleep hygiene, ACT skills (values, committed action), and behavioral change.
Study: NCT04668651

Intervention type: OTHER
Intervention: antral ultrasound
Description: Preoperative evaluation of gastric contents by antral ultrasound

Intervention type: OTHER
Intervention: antral ultrasound
Description: Preoperative evaluation of gastric contents by antral ultrasound
Study: NCT05968898

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Optellum Virtual Nodule Clinic
Description: The Optellum Virtual Nodule Clinic is an FDA-approved (Class II) device for risk stratification of pulmonary nodules. It uses a convolutional neural network to evaluate CT imaging data to provide an estimate of malignancy risk for indeterminate pulmonary nodules.
Study: NCT06134050

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Procedure: HTO using PSI aiming at 55% correction
Description: HTO using PSI designed to achieve correction to 55% tibial width.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Procedure: HTO using PSI aiming at 62% correction
Description: HTO using PSI designed to achieve correction to 62% tibial width.
Study: NCT04656314

Intervention type: DIAGNOSTIC_TEST
Intervention: Functional MRI scan
Description: Functional MRI scan: Phase contrast, BOLD, Arterial Spin Labeling, Diffusion weighted MRI, T1 mapping, T1rho mapping

Intervention type: DIAGNOSTIC_TEST
Intervention: Functional MRI scan
Description: Functional MRI scan: Phase contrast, BOLD, Arterial Spin Labeling, Diffusion weighted MRI, T1 mapping, T1rho mapping
Study: NCT04993235

Intervention type: BEHAVIORAL
Intervention: NEPSY-II
Description: Participants with SS and BWS are administered with selected subtests assessing six different neuropsychological domains

Intervention type: BEHAVIORAL
Intervention: NEPSY-II
Description: Participants with SS and BWS are administered with selected subtests assessing six different neuropsychological domains

Intervention type: BEHAVIORAL
Intervention: CBCL and AQ questionnaires
Description: Parents of participants with SS and BWS are administered with questionnaires assessing behavioral problems and autistic traits

Intervention type: BEHAVIORAL
Intervention: CBCL and AQ questionnaires
Description: Parents of participants with SS and BWS are administered with questionnaires assessing behavioral problems and autistic traits

Intervention type: BEHAVIORAL
Intervention: BUT questionnaire and experimental tasks
Description: A questionnaire, a computer-based task, a body-illusion paradigm and two psychophysical tasks assessing diverse levels of body perception and representation. These tasks are administered to adolescents of the three groups

Intervention type: BEHAVIORAL
Intervention: BUT questionnaire and experimental tasks
Description: A questionnaire, a computer-based task, a body-illusion paradigm and two psychophysical tasks assessing diverse levels of body perception and representation. These tasks are administered to adolescents of the three groups

Intervention type: BEHAVIORAL
Intervention: BUT questionnaire and experimental tasks
Description: A questionnaire, a computer-based task, a body-illusion paradigm and two psychophysical tasks assessing diverse levels of body perception and representation. These tasks are administered to adolescents of the three groups
Study: NCT05335018

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glofitamab, Poseltinib, Lenalidomide
Description: Glofitamab: Increase from 2.5mg for 8days in 1 cycle to 10mg for 15days. 2cycles 1day 30mg, 30 mg on the 1st day of every week thereafter. Poseltinib: 40mg/day bid orally, administered daily from the 1st to the 21st of every week.~Lenalidomide: 20mg/day bid orally, administered daily from the 1st to the 14st of every week.
Study: NCT05351047

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD2373 subcutaneous injection
Description: Randomized subjects will receive multiple ascending dose of AZD2373 by SC injection (dose 1, dose 2, dose 3, dose 4, dose 5).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD2373 subcutaneous injection
Description: Randomized subjects will receive multiple ascending dose of AZD2373 by SC injection (dose 1, dose 2, dose 3, dose 4, dose 5).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD2373 subcutaneous injection
Description: Randomized subjects will receive multiple ascending dose of AZD2373 by SC injection (dose 1, dose 2, dose 3, dose 4, dose 5).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD2373 subcutaneous injection
Description: Randomized subjects will receive multiple ascending dose of AZD2373 by SC injection (dose 1, dose 2, dose 3, dose 4, dose 5).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD2373 subcutaneous injection
Description: Randomized subjects will receive multiple ascending dose of AZD2373 by SC injection (dose 1, dose 2, dose 3, dose 4, dose 5).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Randomized subjects will receive a multiple ascending dose of placebo (saline solution) by SC injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Randomized subjects will receive a multiple ascending dose of placebo (saline solution) by SC injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Randomized subjects will receive a multiple ascending dose of placebo (saline solution) by SC injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Randomized subjects will receive a multiple ascending dose of placebo (saline solution) by SC injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Randomized subjects will receive a multiple ascending dose of placebo (saline solution) by SC injection.
Study: NCT06072989

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: B4T2-001 autologous CAR-T
Description: Each subject will receive multiple intravenous infusions of B4T2-001 autologous CAR-T without preparative chemotherapy (lymphodepletion)
Study: NCT05479279

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neck Stabilization Training Program
Description: 3 times a week stretching exercises approximately 10 mins dumb bell exercises - 2 sets of 15 reps with weights varying from 1 to 2 kg cranio-cervical isometrics for 10 sec with 15 sec breaks between holds with 10-15 reps Tens 5-10 mins Hotpack 5-10 mins neck stretches home plan - 5 reps/set, 3 sets/ day

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional physical therapy
Description: Tens 5-10 mins Hotpack 5-10 mins neck stretches home plan - 5 reps/set, 3 sets/ day
Study: NCT05139849

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vasopressin; Methylprednisolone; Hydrocortisone
Description: Vasopressin, the vasoconstrictive hypophysal hormone, alone has not shown increased survival when compared to adrenaline. However, animal data have shown increased diastolic pressure, cerebral perfusion pressure and cerebral oxygenation in cardiac arrest treatment with vasopressin, and have when compared to adrenaline been associated with better cerebral blood flow.~Corticosteroids are currently used in septic shock treatment as a means to reduce time to shock reversal and thereby potentially improving mortality. Steroids have therefore also been suggested for cardiac arrest treatment. The potential role in resuscitation includes the catecholaminerg potentiation, vasoconstriction and protection from reperfusion injury.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sodium chloride
Description: Sodium chloride 9 mg/ml
Study: NCT04812067

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TTHX1114
Description: engineered FGF-1
Study: NCT05658016

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TK-112690
Description: TK112690 treatment Pre \& Post Radiation

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: TK112690 Placebo treatment Pre \& Post Radiation
Study: NCT04760951

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: TOTUM-070
Description: 5-g dose of TOTUM-070 diet supplement, a mix of 5 plant extracts. Eight capsules per day to consume orally in two intakes

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo. Eight capsules per day to consume orally in two intakes
Study: NCT06061679

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Omron C28P nebuliser
Description: switch from portable inhalers to the Omron C28P nebuliser
Study: NCT06469099

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: excercises
Description: exercises for strength and balance
Study: NCT06178250

Intervention type: OTHER
Group type: OTHER
Intervention: 3D sonography
Description: Fetal liver, placenta, and ductus venosus were defined in 3 orthogonal multi-plane images in the voluson 4D view vocal program.
Study: NCT06085027

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Labor analgesia
Description: Perform epidrual analgesia for parturients between 18 to 45 year-old

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Labor analgesia
Description: Perform epidrual analgesia for parturients between 18 to 45 year-old
Study: NCT05611788

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Structure Learning Training
Description: Participants will undergo 12 sessions of structure learning training lasting about 1 hour each along with 2 testing sessions interspersed within the 12 training sessions. Each session will be conducted in a remote-guided manner with an approximate 1-day gap in between sessions. The entire training will last around two weeks
Study: NCT05017220

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nature-based sensory stimuli
Description: A program based on stimulation using nature-based sensory stimuli will be implemented

Intervention type: OTHER
Group type: OTHER
Intervention: Control group intervention
Description: An activity based on a placebo intervention will be implemented
Study: NCT05058417

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Empagliflozin 10 MG
Description: participants will receive 10 mg Empagliflozin for 8 consecutive weeks in addition to the standard therapy

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: participants will receive placebo for 8 consecutive weeks in addition to the standard therapy
Study: NCT06490393

Intervention type: OTHER
Intervention: Questionnaires
Description: EORTC QLQ-C30 (General Health), EORTC QLQ-SH22(sexual Health), Financial questionnaire as routinely used by the Social Department

Intervention type: OTHER
Intervention: Questionnaires
Description: EORTC QLQ-C30 (General Health), EORTC QLQ-SH22(sexual Health), Financial questionnaire as routinely used by the Social Department
Study: NCT05968599

Intervention type: DRUG
Intervention: Enzalutamide
Description: As provided in real-world setting

Intervention type: DRUG
Intervention: Abiraterone acetate
Description: As provided in real-world setting
Study: NCT05663658

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous morphine patient control device
Description: 24-hour morphine consumption will be recorded

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous morphine patient control device
Description: 24-hour morphine consumption will be recorded

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: External oblique intercostal plane block
Description: External oblique intercostal plane block will be administered before the surgery.
Study: NCT06216184

Intervention type: DIAGNOSTIC_TEST
Intervention: Vortexing
Description: use combined of vortexing and Maki techniques
Study: NCT05234554

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Reproxalap Ophthalmic Solution (0.25%)
Description: Reproxalap Ophthalmic Solution (0.25%) dosed twice.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle Ophthalmic Solution
Description: Vehicle Ophthalmic Solution dosed twice.